Stay up-to-date on new clinical findings in Oncoderm.

Oncoderm Articles

NECOM 3: A Practical Algorithm for the Management of Radiation Therapy-Related Acute Radiation Dermatitis

Background: In the Nordic European countries in 2020, cancer diagnoses accounted for 175,925 patients. About 50% of cancer patients receive radiation therapy (RT), which may lead to radiation dermatitis (RD).

USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events

Background: In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI).

The Interventions to Minimize Pain During Photodynamic Therapy With 5-Aminolevulinic Acid for the Treatment of Cutaneous Diseases

Background: To investigate the effectiveness, safety, patient satisfaction, and cosmetic outcome of Methyl Aminolevulinate-Photodynamic Therapy (MAL-PDT) following curettage in order to make recommendations for its use in dermatology practices.

Non-Invasive Treatment of Basal Cell Carcinoma: Photodynamic Therapy Following Curettage

Photosensitization with 5-aminolevulinic acid (ALA) combined with photodynamic therapy (PDT) is approved in the United States for the treatment of actinic keratosis (AK) and is used off-label for other indications including acne treatment and photo rejuvenation. 

Anti-Tumor Necrosis Factor Alpha Therapeutic Drug Monitoring in Inflammatory Disease: A Systematic Review

Background: Monoclonal antibodies encompass an increasingly important treatment for a variety of dermatologic conditions including hidradenitis suppurativa (HS). The high failure rate and cost of anti-tumor necrosis alpha (TNF-α) agents and emergence of biologic treatments critically warrant treatment strategies that identify treatment failures early and optimize therapy. This review’s primary objective is to understand the current literature on biologic therapeutic drug monitoring (TDM) used in chronic inflammatory diseases and apply this knowledge to future dermatologic studies and treatment.

Utility of Gene Expression Profiling in Skin Cancer: A Comprehensive Review

Understanding the metastatic potential of a skin cancer is essential to effective management. Gene expression profiling (GEP) is an innovative technology that has allowed for a better understanding of tumor biology in various skin cancers. Current methods focus on identifying and quantifying ribonucleic acid (RNA) transcripts in tissue samples. Using reverse transcriptase-polymerase chain reaction, specific RNA transcripts are reverted into deoxyribonucleic acid (DNA) for quantification…

Assessing the Efficacy of Imiquimod Use in Patients With Persistent Locally Advanced Melanoma In Situ

Background: The standard of care when treating melanoma in situ (MMIS) is an excision with at least 5 mm surgical margins.1 Some studies have suggested up to 9 mm margins to maximize local recurrence-free survival.2 This retrospective review aims to assess the efficacy of imiquimod as a topical treatment for persistently positive MMIS at the margins of prior excisions or where surgery is not an option.

Diversifying the Mohs Workforce: Understanding Barriers of Applicants to Mohs Micrographic Surgery Fellowship

Background: The population of the United States is becoming increasingly diverse, yet dermatology, especially Mohs micrographic surgery (MMS), lags behind.

Read More Articles

Oncoderm Editorials

Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment

Shah M, Wald J, Hanke CW. Eruptive Squamous cell carcinomas following treatment with fludarabine and discussion of treatment. J Drugs Dermatol. 2023;22(5):509-510.

Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series

Background: Intralesional 5-fluorouracil (5-FU) is a promising, yet sparsely studied alternative to surgical treatment for nonmelanoma skin cancer (NMSC).1 Previous studies of intralesional 5-FU have reported concentrations ranging from 30 to 50 mg/mL. To the best of our knowledge, this case series represents the first reported use of intralesional 5-FU 10.0 mg/mL and 16.7 mg/mL for NMSC.

Read More Editorials

Advertisement

Podcasts

It Take A Village: Supportive Oncodermatology Perspectives from Oncology Nurse Leaders

The management of any cancer can require a multidisciplinary approach. One of which, until recently, often left the skin side effects on the side walk. Supportive Oncodermatology is positioned to change all that, but to do so requires a team based approach for success. In Part 3 of this supportive oncodermatology mini-series supported by La Roche-Posay, podcast host Dr. Adam Friedman is joined by Dr. Margaret Barton-Burke, PhD, RN, FAAN, Director of Nursing Research at Memorial Sloan Kettering Cancer Center in New York City, and Angela Adames, BSN, RN, OCN, a clinical nurse IV and office practice nurse in the department of radiation oncology at MSKCC, to see this specialty through a different lens. Collaboration is the name of the game and there is plenty of opportunity to do so – tune in to hear how and join the fight against oncologic therapy side effects.

This podcast series is supported by La Roche-Posay.
Listen Now

Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved

While the old adage, “more oncology treatments, more skin problems,” becomes more like dogma every day with each new life saving therapy, fear not my friends, help is out there. Joining JDD podcast host Dr. Adam Friedman again, the man, the myth, the supportive oncodermatology legend, Dr. Mario Lacouture shares the latest guidance on managing these hair, skin and nail toxicities that are often considered by the patient even worse then the cancer these drugs treat. Get your support on – your patients will thank you.
This podcast series is supported by La Roche-Posay.
Listen Now

Heal the Burn: Radical Updates for the Management of Radiation Dermatitis

All of those wonderful life saving toys the radiation oncologists get to play with come at a cost to an important bystander – the skin. Radiation dermatitis can be exquisitely disabling, and interfere with a patient’s treatment course. Enter Dr. Beth McLellan, Chief of Dermatology at the Albert Einstein College of Medicine who is soothing XRT burns and taking names. Tune in to part two of this three part supportive oncodermatology series as host Dr. Adam Friedman discusses how to best coordinate care with our oncology friends and manage and hopefully prevent this expected adverse event with this one rad derm. Phasers set to educate.
This podcast series is supported by La Roche-Posay.

 

Listen Now

Supplements

United States Cutaneous Oncodermatology Management (USCOM) III: A Multidisciplinary-Guided Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events in Cancer Patients

In 2023, nearly 2 million patients will be diagnosed with cancer in the United States and at least 40% will be eligible for treatment with an immune checkpoint inhibitor (ICI). Cutaneous immune-related adverse events (cirAEs) from ICIs are common and include pruritus as well as maculopapular, eczematous, bullous, lichenoid, and psoriasiform reactions. All clinicians interfacing with cancer patients must expedite proper evaluation and diagnosis, treatment, and/or consultation that supports the need for evidence-directed guidelines.

Read More

Nordic European Cutaneous Oncodermatology Management (NECOM) 3: A Practical Algorithm for Acute Radiation Dermatitis Management for Cancer Patients Receiving Radiation Therapy

In the Nordic European countries in 2020, cancer diagnoses accounted for 175,925 patients. About 50% of cancer patients receive radiation therapy (RT), which may lead to radiation dermatitis (RD). Notably, patients with breast, head, neck, and anal cancers may be prone to developing RD. However, few algorithms exist for the prevention and treatment of RD.

Read More

US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm

An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients’ quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cAEs.

Read More